Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEOPARD: lenvatinib plus hepatic arterial infusion cisplatin for advanced hepatocellular carcinoma
jRCTs031180019Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and cisplatin in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoint: Objective response rate (modified RECIST, independent review). Started Oct 2018; status: completed.
02
Drugs
lenvatinibcisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031180019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180019.